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Foreword
The control of viral diseases has been a long crusade for the biomedical investigator. Two approaches have evolved for the control of viral infections. First, since the successful development of a smallpox vaccine by Jenner over two centuries ago, efforts directed at the control of viral infections have focilsed for the most part on prophylaxis by vaccination. Significant advances in vaccination have been achieved for the prevention of rubella, measles, polio, and rabies. These accomplishments have had a major impact on worldwide public health. Even more notably, we have witnessed the eradication of smallpox through a combined effort co-ordinated by the World Health Organization. However, the physician today encounters viral diseases for which contemporary technology has not provided quick and simple mechanisms of prevention. The unique propensities of some viruses and social limitations have not allowed for the proper application of some existing vaccines. From a social organization standpoint, the simple lack of uniform refrigeration in many Third World countries and the inordinate costs of vaccine preparation, deployment and delivery in man hours have prevented successful universal immunization against measles and polio. Advances in viral genetics and the biochemistry of both viral replication and host response are leading to the development of immunogens which, hopefully, will be of clinical benefit, albeit many years from realization. These immunogens have been predicated upon utilization of contemporary viral genetic engineering, the synthetic production of immunogens and the cloning of key microbial elements.
Drs. Oxford and Oberg have taken a broad and comprehensive view of the complex problems encountered in developing prophylaxis of viral diseases. In so doing, the vaccine successes of smallpox, measles and polio are contrasted with the inherent problems encountered in the development of vaccines to prevent herpesvirus, influenza, and rhinovirus 'ihfections. Because of these inherent difficulties, alter-native methods for the control of viral diseases have led to the second approach, namely, utilization of therapeutics as chemotherapy, interferon, or biologic response modifiers. The herpesviruses as a group have spearheaded the development of antiviral chemotherapeutics.
Antiviral therapy for human viral infections has evolved slowly over the past twenty-five years and far more so than the development of vaccines. The first series of antiviral agents tested in clinical trials arose from screening programmes for the development of anti-cancer drugs. These drugs were identified as 'first generation' antiviral agents because of their non-selective inhibition of both host cell and viral replication and include idoxuridine, cytosine arabinoside and vidarabine. In the early 1960s, idoxuridine was shown to have clinical activity for topical therapy of herpes simplex keratoconjunctivitis in animals and humans. This observation set the stage for the realization that antiviral therapy could be effective for the treatment of human disease. While idoxuridine was under development, amantadine, a cyclic amine, was established as useful for prevention of influenza A infections. As recently as five years ago, little clinical attention was paid to amantadine, in spite of clinical efficacy, because of the concern for potential toxicity following prophylactic administration. However, many of these concerns have been alleviated with its use as a therapeutic for Parkinson's disease. More recently, rimantidine has attracted clinical interest because of less toxicity.
During the 1970s, vidarabine was shown to be effective against life-threatening human viral infections, being proved useful for the treatment of herpes simplex encephalitis, varicella-zoster virus infections in the immunocompromised host (shingles and chickenpox), and neonatal herpes simplex virus infection.
During the late 197Os, the first of the 'second generation' antiviral drugs, namely selective inhibitors of viral replication, began to enter clinical investigations. Acyclovir is the prototype of these drugs, being selectively activated by an enzyme unique to herpesvirus replication, herpes simplex thymidine kinase. Subsequently, it has been shown useful for the treatment of primary genital herpes simplex virus infections and severe progressive mucocutaneous herpes simplex virus infections when administered by either parenteral or topical routes. The recognition of acyclovir's ability to inhibit herpesvirus replication was a fortuitous observation rather than one strategically planned to utilize enzymes unique to herpesvirus replication. Nevertheless, the scientific advances offered by the synthesis and development of acyclovir for treatment of human herpesvirus infections are significant. In essence, its development will allow for the more rational development of antiviral agents in the future.
Other second generation compounds are receiving attention for treatment of herpesvirus infections. These include phosphonoformatea compound being extensively studied for herpes simplex and cytomegalovirus infections in Sweden; bromovinyl deoxyuridinea compound currently under evaluation for shingles and chickenpox in Belgium; and ribavirina compound being assessed for treatment ix of respiratory syncytial virus and influenza infections as well as some of the more common herpesvirus infections. In the immediate future, additional analogues of acyclovir such as dihydroxypropoxy methyl guanine will be entering phase I clinical evaluations. Thus, a great deal of interest has evolved for the development of antiviral drugs both in academia and in industry.
In spite of the advances in the treatment of herpesvirus infections, several pieces of the puzzle leading to successful therapy of human viral disease remain strikingly elusive. These pieces are applicable to the successful therapy of all viral infections and not just those of the herpesvirus family. One significant missing piece of data is our lack of understanding of the mechanisms by which all herpesviruses establish latency and subsequently recur. Even with the introduction of antiviral therapy early in the disease course for primary genital herpes simplex virus infections, it has not been possible to significantly alter the frequency of recurrences let alone completely prevent them, regardless of the mode of drug delivery. Thus, although therapy may be of clinical benefit for the acute episode of disease, it does not alter the subsequent frequency or severity of recurrences. The development of medications to achieve this endpoint will require strategies different from those currently available. For other viruses, a better understanding of the common mechanisms of rhinovirus replication is essential for the development of specific drugs as the numerous serotypes preclude utility of a vaccine.
Since most viral infections lead to peak progeny viral production prior to the onset of clinical symptomatology, it becomes encumbent upon the biomedical investigator to identify diagnostic procedures which would allow for early and specific identification of patients with infection. Utilization of contemporary principles of molecular biology for the development of specific antiviral agents and for rapid diagnostics will likely redefine the natural history of many human viral infections, allowing the selection of populations at high risk for development of infection and for whom prophylactic antivirals or improved vaccines might prove useful. Examples would include family members at risk for development of rhinovirus or coronavirus infection, sexual partners of individuals with genital herpes simplex virus infection, or immunocompromised patients at risk for development of cytomegalovirus infection. If diagnostic procedures are improved, prophylactic antivirals might prove useful.
Drs. Oxford and Oberg's book addresses these issues in detail, providing insight in the directions mandatory for further improvement of the control of viral infections. Our current understanding of viral infections and the need to develop drugs which act at specific targets of viral replication can only lead to further improvement in the treatment and management of viral infections of humans. These insights will require the careful melding of talents of both the basic scientist and the clinical investigator.
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